Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Pfizer’s Eucrisa Approval By FDA Adds New Dermatology Anchor
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results
Deal Watch: Anacor Purchase Marks Pfizer's Post-Allergan Bolt-On Strategy
Flexion's OA Knee Injection On Track For H2 Filing
Keeping Track: New Year, New Submissions Roll In To FDA
AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel